



19<sup>th</sup> Executive Board  
 Special Session on Proposals  
 5 May 2014  
 WHO, Geneva

**Resolution n°1**  
**Expand New Drug Markets for TB (END-TB)**

Taking into account the outcome of the PRC review of 3-4 April 2014 and noting the issues raised for further clarification, the Executive Board of UNITAID, subject to the availability of funds, authorizes the Executive Director to commit up to **USD 60 369 772** for the project *Expand New Drug Markets for TB (END-TB)*.

**Description:** END-TB aims to radically change the MDR-TB (multidrug resistant tuberculosis) market by accelerating uptake of the newly released MDRTB drugs (bedaquiline and delamanid) in 17 countries. The intervention will have long-term market effects that will consolidate the market for MDR-TB drugs, expanding access to new, effective, and user-friendly treatment regimens for patients with MDR-TB.

**Lead organization(s):** Partners in Health


**Consortium members:** Médecins sans Frontières France on behalf of MSF France, MSF Holland, MSF Switzerland and MSF AC; Interactive Research and Development

**Project duration:** 4 years

**Conditions for UNITAID funding support:**

Funding is conditional upon:

- The development of a Project Plan to the satisfaction of the Secretariat, having regard to the issues raised by the PRC during its review.
- Review of the budget to ensure that it includes sufficient resources for centralized oversight, whilst also ensuring that all proposed costs are appropriate and reasonable (including with respect to any third-party recipients), to the satisfaction of the Secretariat.
- Signature of a legal agreement between Partners in Health and UNITAID.

PP 

Philippe Douste-Blazy  
 Chair of the UNITAID Executive Board